BRAF and neuroendocrine carcinoma: There are occasional case reports of targeted treatment of BRAF V600E mutated pancNETs as well as poorly differentiated neuroendocrine carcinoma (NEC) of GI origin with varying results; however, this is the first report of D/T treatment specific to NET G3 of pancreatic origin [26, 30, 31].